Monopar Therapeutics Shares Rise 12% Premarket After Patient Dosing
By Chris Wack
Monopar Therapeutics Inc. shares rose 12% to $5.10 in premarket
trading after the company said the first patient has been dosed in
its open-label dose-escalation Phase 1b clinical trial evaluating
camsirubicin for the treatment of advanced soft tissue sarcoma.
The biopharmaceutical company received U.S. Food and Drug
Administration allowance to proceed in early August.
Monopar said an estimated 21 patients will be enrolled in the
Phase 1b clinical trial, which is active and recruiting in the
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires
October 27, 2021 09:24 ET (13:24 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.